切除不能または転移性腎細胞癌患者の二次治療におけるボロラニブ
切除不能または転移性腎細胞癌患者の二次治療におけるボロラニブの有効性と安全性に関する観察研究
This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.
調査の概要
状態
詳細な説明
This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted. Vorolanib is a new generation of multi-target kinase inhibitors with a new chemical structure, which can inhibit tumor angiogenesis and growth, and is used in the treatment of various cancers. This multicenter, single-arm, open-labelled observational study is designed to include patients who meet the requirements for using vorolanib as a second-line treatment for renal cell carcinoma. For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Le Qu, M. D.
- 電話番号:+86 15720625951
- メール:septsoul@hotmail.com
研究場所
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、401520
- 募集
- Jinling Hospital
-
コンタクト:
- Le Qu, M. D.
- 電話番号:+86 15123894157
- メール:septsoul@hotmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Subjects clinically diagnosed with advanced unresectable or metastatic renal cell carcinoma. After receiving at least one systemic therapy (including TKIs or TKIs combined with ICIs, including but not limited to axitinib, sunitinib, sorafenib, pembrolizumab, etc.), subjects reach PD as assessed by RECIST v1.1 and switch to second-line treatment options including vorolanib.
説明
Inclusion Criteria:
- Subjects have fully understood and voluntarily signed the informed consent form (ICF);
- 18-80 years old (at the time of signing the informed consent); Both men and women; ECOG PS score: 0-1;
- Renal cell carcinoma with clear cell components confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma dominated by clear cell components;
- According to RECIST (version 1.1), there are targets that are considered to be observable;
- The main organs function well.
Exclusion Criteria:
- A history of malignancies other than the disease studied within the past 5 years, other than malignancies that are expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery);
- Systemic treatment with other antitumor agents, including targeted agents, immunotherapy agents and their combination regimens (eligible for inclusion after 5 half-lives), local antitumor therapy, or clinical investigational drug or device therapy within 4 weeks prior to the initial study;
- Had major surgery within 4 weeks prior to initial study dosing (as judged by the investigator) or was in recovery;
- A history of severe drug allergy, including but not limited to antibody drugs;
- Patients with contraindications for immunotherapy restart;
- A known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation may require long-term adrenal corticosteroid therapy. Patients with thyroid, suprarenal, or hypopituitarism that can be controlled by hormone replacement therapy alone, type 1 diabetes mellitus, and psoriasis or vitiligo that do not require systemic treatment are eligible to participate in this study;
- Toxicity did not resolve after previous antitumor therapy, i.e., regression to baseline, NCI-CTCAE 5.0 level 0-1 (except for alopecia), or levels specified in inclusion/exclusion criteria. Irreversible toxicity (e.g., hearing loss) that is not reasonably expected to be aggravated by the drug under study may be included in the study;
- Have central nervous system metastases and/or cancerous meningitis;
- Known history of clinically significant liver disease, including those infected with viral hepatitis activity;
- Patients with uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients with no need to drain effusion or no significant increase in effusion after 3 days of stopping drainage could be included);
- Patients with any severe and/or uncontrolled disease;
- Renal failure requires hemodialysis or peritoneal dialysis;
- Have or have a suspected active autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.;
- History of live attenuated vaccine vaccination within 4 weeks prior to the initial study or expected live attenuated vaccine vaccination during the study period;
- Those who have a history of psychotropic drug abuse and cannot abstain or have a history of mental disorders;
- Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities, as determined by the investigator, that may increase the risks associated with study participation or that may interfere with the interpretation of the study results.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:OTHER
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Experimental cohort.
Subjects who progressed after first-line treatment and switched to second-line treatment regimens including vorolanib. The first-line treatment which patients received can be other tyrosine kinase inhibitors (TKIs) or TKIs combined with immunotherapy drugs. Provided vorolanib is contained in the second-line regimen, the patient then can be considered for inclusion in the study. |
For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
無増悪生存期間 (PFS)
時間枠:登録から12週間の治療終了まで。
|
登録から12週間の治療終了まで。
|
|
治療関連有害事象 (TRAE)
時間枠:登録から治療後 12 週間または報告後最大 90 日まで。
|
登録から治療後 12 週間または報告後最大 90 日まで。
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
全体的な生存 (OS)
時間枠:登録から12週間の治療終了まで。
|
登録から12週間の治療終了まで。
|
|
客観的応答率 (ORR)
時間枠:登録から12週間の治療終了まで。
|
登録から12週間の治療終了まで。
|
|
疾病制御率 (DCR)
時間枠:登録から12週間の治療終了まで。
|
登録から12週間の治療終了まで。
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:Yuxiu Liu, M. D.、Jinling Hospital, China
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2024DZKY-074-02
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。